多西他赛治疗晚期非小细胞肺癌的临床观察

Clinical study of docetaxel for advanced non-small cell lung cancer

为了观察多西他赛(泰索帝)每周给药方案和3周给药方案治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应,对112例患者,随机分为实验组(多西他赛每周组)和对照组(多西他赛3周组)。实验组:多西他赛35mg/m2,静脉滴入,d1、d8、d15;顺铂(DDP)75mg/m2,静脉滴入,d1;对照组:多西他赛75mg/m2,静脉滴入,d1;DDP80mg/m2,分3次于d1、d2、d3,静脉滴入,28d为1个周期。至少完成2个周期。结果:实验组有21例患者部分缓解,占全部入组病例的38.18%,高于对照组3周方案有效率31.58%(18/57),其中鳞癌有效率50.00%(12/24)明显好于对照组34.62%(9/26),P<0.05。Ⅲ～Ⅳ度粒细胞减少为10.09%(6/55),较对照组26.32%(15/57)明显减少,实验组体液潴留及胃肠道反应多于对照组,分别为23.64%(13/55)和12.73%(7/55),P<0.05。其他不良反应与对照组比较差异无统计学意义。初步研究结果提示,多西他赛每周给药联合DDP治疗晚期NSCLC疗效较好,骨髓毒性较轻。

The objective of this study was to study the efficacy and safety of docetaxel administrated weekly plus cisplatin in the treatment of patients with advanced non small cell lung cancer （NSCLC）. One hundred and twelve consenting pa tients with adwmced NSCLC were randomly divided into experiment group （docetaxel 35 mg/m^2, iv, d1, d8, d15; DDP 75 mg/m^2, iv, d1 ） and control group （docetaxel 75 mg/m^2 , iv, d1 ; DDP 80 mg/m^2 , iv, d1 , d2, d3, 28 days as a cycle）. The overall response rate were 31.58% in experiment group and 38.18% in control group, P〈0.05. Grade Ⅲ and Ⅳ leukopenia in expersiment group （10.09 %） was significantly lower than that in control group （26.32 %）. The fluid retention and gastrointestinal reaction in experiment group （23.64%） was significantly higher than that in control group （12.73 % ）, P〈0.05. In conclusion, the weekly schedule of docetaxel plus cisplatin combination as first-line chemotherapy for advanced NSCLC, while feasible, has an advantage over the standard 3 weekly regimen.